JP2019501208A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501208A5
JP2019501208A5 JP2018541089A JP2018541089A JP2019501208A5 JP 2019501208 A5 JP2019501208 A5 JP 2019501208A5 JP 2018541089 A JP2018541089 A JP 2018541089A JP 2018541089 A JP2018541089 A JP 2018541089A JP 2019501208 A5 JP2019501208 A5 JP 2019501208A5
Authority
JP
Japan
Prior art keywords
rsv
vaccine
pseudouridine
thio
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018541089A
Other languages
English (en)
Japanese (ja)
Other versions
JP7687767B2 (ja
JP2019501208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/058321 external-priority patent/WO2017070622A1/en
Publication of JP2019501208A publication Critical patent/JP2019501208A/ja
Publication of JP2019501208A5 publication Critical patent/JP2019501208A5/ja
Priority to JP2022172576A priority Critical patent/JP2023015151A/ja
Priority to JP2024227631A priority patent/JP2025041835A/ja
Application granted granted Critical
Publication of JP7687767B2 publication Critical patent/JP7687767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018541089A 2015-10-22 2016-10-21 呼吸器合胞体ウイルスワクチン Active JP7687767B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022172576A JP2023015151A (ja) 2015-10-22 2022-10-27 呼吸器合胞体ウイルスワクチン
JP2024227631A JP2025041835A (ja) 2015-10-22 2024-12-24 呼吸器合胞体ウイルスワクチン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562245031P 2015-10-22 2015-10-22
US201562245208P 2015-10-22 2015-10-22
US62/245,031 2015-10-22
US62/245,208 2015-10-22
US201562247563P 2015-10-28 2015-10-28
US62/247,563 2015-10-28
US201562248250P 2015-10-29 2015-10-29
US62/248,250 2015-10-29
PCT/US2016/058321 WO2017070622A1 (en) 2015-10-22 2016-10-21 Respiratory syncytial virus vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022172576A Division JP2023015151A (ja) 2015-10-22 2022-10-27 呼吸器合胞体ウイルスワクチン
JP2024227631A Division JP2025041835A (ja) 2015-10-22 2024-12-24 呼吸器合胞体ウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2019501208A JP2019501208A (ja) 2019-01-17
JP2019501208A5 true JP2019501208A5 (enExample) 2019-12-05
JP7687767B2 JP7687767B2 (ja) 2025-06-03

Family

ID=58558153

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018541089A Active JP7687767B2 (ja) 2015-10-22 2016-10-21 呼吸器合胞体ウイルスワクチン
JP2022172576A Pending JP2023015151A (ja) 2015-10-22 2022-10-27 呼吸器合胞体ウイルスワクチン
JP2024227631A Pending JP2025041835A (ja) 2015-10-22 2024-12-24 呼吸器合胞体ウイルスワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022172576A Pending JP2023015151A (ja) 2015-10-22 2022-10-27 呼吸器合胞体ウイルスワクチン
JP2024227631A Pending JP2025041835A (ja) 2015-10-22 2024-12-24 呼吸器合胞体ウイルスワクチン

Country Status (20)

Country Link
US (2) US20180271970A1 (enExample)
EP (1) EP3365008A4 (enExample)
JP (3) JP7687767B2 (enExample)
KR (1) KR20180096592A (enExample)
CN (1) CN108472354A (enExample)
AU (1) AU2016341311B2 (enExample)
BR (1) BR112018008102A2 (enExample)
CA (1) CA3002820A1 (enExample)
CL (1) CL2018001053A1 (enExample)
CO (1) CO2018005229A2 (enExample)
EA (1) EA201891000A1 (enExample)
IL (1) IL258831A (enExample)
MA (1) MA46317A (enExample)
MX (1) MX2018004917A (enExample)
PE (1) PE20181530A1 (enExample)
PH (1) PH12018500856A1 (enExample)
SG (2) SG11201803363YA (enExample)
TN (1) TN2018000154A1 (enExample)
TW (1) TW201729836A (enExample)
WO (1) WO2017070622A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
PT3386484T (pt) 2015-12-10 2022-08-01 Modernatx Inc Composições e métodos para entrega de agentes terapêuticos
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP4631970A3 (en) * 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3595713A4 (en) * 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. WIDE SPECTRUM INFLUENZA VIRUS VACCINE
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
JP7550648B2 (ja) 2018-03-19 2024-09-13 クリスパー セラピューティクス アーゲー 新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
US11576960B2 (en) 2018-03-30 2023-02-14 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (RSV) vaccines
SG11202008225PA (en) 2018-04-17 2020-11-27 Curevac Ag Novel rsv rna molecules and compositions for vaccination
EP3833382A1 (en) * 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
JP7526168B2 (ja) 2018-09-19 2024-07-31 モデルナティエックス インコーポレイテッド Peg脂質及びそれらの使用
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) * 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
CN113710799B (zh) 2018-11-28 2024-11-12 克里斯珀医疗股份公司 用于在LNP中使用的编码CAS9的优化mRNA
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
EP3927821A4 (en) 2019-02-20 2023-01-25 ModernaTX, Inc. RNA POLYMERASE VARIANTS FOR CO-STRANSCRIPTION CAPTING
JP2022521760A (ja) * 2019-02-28 2022-04-12 ノババックス,インコーポレイテッド Rsv感染によって引き起こされる疾患又は障害を予防する方法
JP2022526089A (ja) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド 流加バッチインビトロ転写プロセス
EP3937963B1 (en) 2019-03-12 2025-05-07 CRISPR Therapeutics AG Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN114957407A (zh) * 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
CN115778904B (zh) * 2019-10-29 2025-03-28 珠海丽凡达生物技术有限公司 一种用于体外转染和体内递送mRNA的制剂
CN115103682A (zh) * 2020-01-30 2022-09-23 摩登纳特斯有限公司 呼吸道病毒免疫组合物
AU2021261471B2 (en) 2020-04-22 2024-10-24 BioNTech SE Coronavirus vaccine
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
JP2023533721A (ja) 2020-07-02 2023-08-04 ライフ テクノロジーズ コーポレーション トリヌクレオチドキャップ類似体、それらの調製、及び使用
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN111973563B (zh) * 2020-09-02 2022-06-28 崔海港 一种鼠李糖脂冻干粉制剂及其制备方法和应用
TW202233232A (zh) * 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
KR20240021218A (ko) 2021-06-11 2024-02-16 바이엘 악티엔게젤샤프트 신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
AU2022336209B2 (en) 2021-09-03 2025-10-16 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
AU2023284048A1 (en) 2022-06-10 2024-11-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN120153078A (zh) * 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
AU2023398007A1 (en) 2022-12-13 2025-06-19 Bayer Aktiengesellschaft Engineered type v rna programmable endonucleases and their uses
AU2023427858A1 (en) * 2023-02-03 2025-05-15 Vernagen, LLC Respiratory syncytial virus mrna vaccine
CN116286672B (zh) * 2023-02-07 2025-01-28 金宇保灵生物药品有限公司 一种口蹄疫病毒及其应用
WO2024179559A1 (en) * 2023-03-02 2024-09-06 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for respiratory syncytial virus (rsv)
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
WO2024194153A1 (en) * 2023-03-17 2024-09-26 Glaxosmithkline Biologicals Sa Rsv-f-encoding nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024260359A1 (zh) * 2023-06-20 2024-12-26 石药集团巨石生物制药有限公司 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法
WO2024259624A1 (en) * 2023-06-21 2024-12-26 Shenzhen Genius Biotech Service Co. Ltd A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection
CN119490569A (zh) * 2023-08-16 2025-02-21 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用
CN117487823B (zh) * 2023-09-28 2024-10-29 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用
CN118480560B (zh) 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
CA2462593A1 (en) 2001-10-03 2003-04-10 Kam W. Leong Compositions for oral gene therapy and methods of using same
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
AU2005329255B2 (en) 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
US7638558B2 (en) 2005-04-01 2009-12-29 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
AU2007292902B8 (en) 2006-09-08 2013-09-05 Johns Hopkins University Compositions and methods for enhancing transport through mucus
JP5452230B2 (ja) 2006-12-21 2014-03-26 ストライカー コーポレイション 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
PL2644192T3 (pl) 2007-09-28 2017-09-29 Pfizer Inc. Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
KR20160116062A (ko) 2008-06-16 2016-10-06 바인드 쎄라퓨틱스, 인크. 약물 부하된 중합체성 나노입자, 및 이의 제조 및 사용 방법
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
ES2654533T3 (es) 2008-06-16 2018-02-14 Pfizer Inc. Procedimientos para la preparación de copolímeros dibloque funcionalizados con un agente de direccionamiento para su uso en la fabricación de nanopartículas terapéuticas
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
CA2743139C (en) * 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
EP3243504A1 (en) * 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2011084521A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP5988435B2 (ja) 2010-01-24 2016-09-07 ノバルティス アーゲー 放射線照射された生分解性微粒子
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
WO2011163483A2 (en) 2010-06-25 2011-12-29 Massachusetts Institute Of Technology Polymers for biomaterials and therapeutics
EP2590676B1 (en) * 2010-07-06 2016-08-17 GlaxoSmithKline Biologicals SA Virion-like delivery particles for self-replicating rna molecules
HUE026646T2 (en) * 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
PL2591114T3 (pl) * 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
EP2635254B1 (en) 2010-11-05 2019-05-15 The John Hopkins University Compositions and methods relating to reduced mucoadhesion
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
US20140066363A1 (en) 2011-02-07 2014-03-06 Arun K. Bhunia Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
EP2691078A1 (en) 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US9901554B2 (en) 2011-03-31 2018-02-27 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
JP2014520806A (ja) * 2011-07-06 2014-08-25 ノバルティス アーゲー Rna分子の送達のための有用なn:p比を有するリポソーム
EP3456316A1 (en) * 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
ES2670944T3 (es) 2011-07-21 2018-06-04 Croda International Plc Copolímeros de bloques de poliéter-poliamida ramificados y métodos de preparación y uso de los mismos
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US8889657B2 (en) 2011-08-31 2014-11-18 Mallinckrodt Llc Nanoparticle PEG modification with H-phosphonates
JP2014531456A (ja) 2011-09-22 2014-11-27 バインド セラピューティックス インコーポレイテッド 治療用ナノ粒子と癌を治療する方法
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
EP3597644B1 (en) 2011-10-18 2021-09-29 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
HRP20220717T1 (hr) * 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
AU2013209452B2 (en) 2012-01-19 2015-11-05 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CA2863203C (en) 2012-02-03 2020-03-24 Rutgers, The State Of University Of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
EP2812383A1 (en) 2012-02-10 2014-12-17 E. I. Du Pont de Nemours and Company Preparation, purification and use of high-x diblock copolymers
JP6189415B2 (ja) * 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドModernaTX,Inc. 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
HK1208618A1 (en) * 2012-06-08 2016-03-11 夏尔人类遗传性治疗公司 Pulmonary delivery of mrna to non-lung target cells
ES2968649T3 (es) * 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
EP4421177A3 (en) * 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
SMT202100430T1 (it) * 2013-03-14 2021-09-14 Translate Bio Inc Metodi e composizioni per il rilascio di anticorpi codificati da mrna
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP4614148A3 (en) * 2013-03-15 2025-12-17 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
JP6685903B2 (ja) * 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたrsv融合前fタンパク質
BR112016003361A2 (pt) * 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК

Similar Documents

Publication Publication Date Title
JP2019501208A5 (enExample)
US12240873B2 (en) Respiratory syncytial virus (RSV) vaccine
JP2018536023A5 (enExample)
JP2018531996A5 (enExample)
JP2019535665A5 (enExample)
JP2021504445A5 (enExample)
RU2018118337A (ru) Вакцина против вируса гриппа широкого спектра действия
US10751407B2 (en) PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
RU2016145597A (ru) Вакцины на основе нуклеиновых кислот
WO2014134439A1 (en) Immunogenic composition for mers coronavirus infection
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
US11274282B2 (en) Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
JP7801221B2 (ja) 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用
EP3035960B1 (en) Respiratory syncytial virus (rsv) vaccine
CA3130956A1 (en) Novel vaccine effective to prevent infection by sars-cov variants
US20230364220A1 (en) SAR-COV-2 DNA Vaccine and Method of Administering Thereof
WO2024073552A2 (en) Combination exosomal immunogenic compositions and methods
WO2024249651A2 (en) Sars cov-2 vaccines, associated polynucleotides, and methods of use
CN119264229A (zh) 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物
HK40057100A (en) Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
CN120359299A (zh) 一种广谱流感mRNA疫苗
Tachibana et al. 666. Type-I IFN Signaling Is Required for the Induction of Antigen-Specific CD8+ T Cell Responses by Adenovirus Vector Vaccine in the Gut-Mucosal Compartment
EA041575B1 (ru) Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения